Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro

LEVERKUSEN, Germany Wed Nov 14, 2012 3:17pm IST

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   
Coal Mining In The Punjab

Coal Mining In The Punjab

In Choa Saidan Shah miners dig coal with crude pick axes and load it onto donkeys to be transported to the surface earning a team of 4 workers around $10 to be split between them.  Slideshow 

LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

(Reporting by Frank Siebelt; Writing by Ludwig Burger)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak

REUTERS SHOWCASE

Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage